Navigation Links
Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:9/26/2013

re 13 deaths: six in the placebo group, three in the low-dose group, three in the mid-dose group and one in the high-dose group. Finally, persistence of the vector DNA as assessed by qPCR testing was demonstrated in three high dose MYDICAR patients in whom a biopsy was feasible, but not from patients in the placebo or lower dose groups.  No safety concerns were noted during the three year follow-up period.

About the CUPID 1 Trial
Phase 2a of the CUPID 1 trial was a clinical trial using Celladon's lead product candidate MYDICAR in patients with advanced heart failure. In this 39-patient trial, MYDICAR was found to be safe and well-tolerated, reduced heart failure-related hospitalizations, improved patients' symptoms and quality of life, and improved key markers of cardiac function predictive of survival, such as elevated levels of natriuretic peptides and end systolic volume.  Three dose levels of MYDICAR were administered, and the high-dose MYDICAR group met the primary endpoint versus placebo at six months, and all positive trends were confirmed at 12 months. The hazard ratio at 12 months for the high-dose MYDICAR group versus placebo for recurrent adjudicated clinical events was 0.12 (p=0.003) representing a risk reduction of 88% with MYDICAR versus placebo. No safety concerns were noted.

About Celladon
We are a clinical-stage biotechnology company applying our leadership position in the field of calcium dysregulation by targeting SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, diabetes and neurodegenerative diseases. Our therapeutic portfolio for diseases characterized by SERCA enzyme defic
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Luminex Corporation to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... KYOTO and OSAKA, Japan ... iPS Cell Research Application (CiRA) of Kyoto University ... that they will work together to develop clinical ... such as heart failure, diabetes mellitus, neurological disorders ... iPS Cell Applications" (T-CiRA) is designed to expedite ...
(Date:4/16/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... on Thursday, April 30, 2015 at 4:00 PM Eastern ... a conference call at 4:30 PM Eastern Time to ... for the future. , The conference call will be ... and in the Investor Relations section of Cytokinetics’ website ...
(Date:4/16/2015)... Proove Biosciences , Inc. is pleased ... for the 2015 BIO International Convention. Hosted by ... Convention will take place June 15-18 at the Pennsylvania ... BIO contest, industry leaders will be voting for companies ... The community voting period began on April 14, 2015 ...
(Date:4/16/2015)... 16, 2015 Regis Technologies looks forward ... for Cancer Research (AACR) annual meeting. Regis will exhibit ... starting Saturday, April 18, in Philadelphia and running through ... title of the oldest and largest organization focused on ... grants, and partners with survivors to promote awareness and ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2
... ESD Contract Vehicle makes ViPS Member of Select Group of Companies, Permitted ... ... Next 10 Years Maximum of $4 Billion in Contract Value ... (Nasdaq: HLTH ) ViPS subsidiary today announced that ViPS has,been selected as ...
... CITY, Calif., Sept. 18 Ingenuity Systems, ... and interpret scientific,literature and data, is pleased ... a major public-private biomedical research,partnership created to ... support new drug development, preventive medicine, and ...
... of billiards may never get smaller than this. , ... one-atom thick sheet of carbon atoms arranged in hexagonal rings ... charges acting as billiard balls. , The finding underscores ... as silicon, that can be used to develop new kinds ...
Cached Biology Technology:ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS 2ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS 3Ingenuity Systems Joins Biomarkers Consortium 2Sheet of carbon atoms acts like a billiard table, physicists find 2
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... 2011) The Damon Runyon Cancer Research Foundation, ... career researchers, named 18 new Damon Runyon Fellows ... The recipients of this prestigious, three-year award are ... research in the laboratories of leading senior investigators ...
... NY, July 6, 2011A policy specialist and a healthcare ... billion to bring a new drug to market does ... Engineering & Biotechnology News (GEN). The researchers emphasize ... numbers are subject to numerous internal and external sources ...
... a compact fluorescent light bulb continuously releases mercury vapor ... total amount can exceed safe human exposure levels in ... in Environmental Engineering Science , a peer-reviewed online ... (www.liebertpub.com). The article is available free online at ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 5Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 6GEN point of view article questions reported costs of drug R&D 2Mercury vapor released from broken compact fluorescent light bulbs can exceed safe exposure levels 2
Mouse monoclonal [164-12-2] to Ampicillin ( Abpromise for all tested applications)....
Flotillin-2 (ESA) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 29, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
... Rabbit polyclonal to Kv4.2 Immunogen ... KLH, corresponding to amino acids 23-43 of ... Cross-reacts with Rat.Expected to cross-react with Human ... with immunogen), Rabbit (100% identity with immunogen) ...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
Biology Products: